- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01778049
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes
A Phase III, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Linagliptin 5 mg Compared to Placebo, Administered as Oral Fixed Dose Combination With Empagliflozin 10 mg or 25 mg for 24 Weeks, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks of Treatment With Empagliflozin 10 mg or 25 mg on Metformin Background Therapy
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Caba, Argentina
- 1275.10.54005 Boehringer Ingelheim Investigational Site
-
Caba, Argentina
- 1275.10.54012 Boehringer Ingelheim Investigational Site
-
Capital Federal, Argentina
- 1275.10.54002 Boehringer Ingelheim Investigational Site
-
Capital Federal, Argentina
- 1275.10.54007 Boehringer Ingelheim Investigational Site
-
Capital Federal, Argentina
- 1275.10.54013 Boehringer Ingelheim Investigational Site
-
Cordoba, Argentina
- 1275.10.54006 Boehringer Ingelheim Investigational Site
-
Cordoba, Argentina
- 1275.10.54008 Boehringer Ingelheim Investigational Site
-
Córdoba, Argentina
- 1275.10.54011 Boehringer Ingelheim Investigational Site
-
Godoy Cruz, Mendoza, Argentina
- 1275.10.54003 Boehringer Ingelheim Investigational Site
-
Mar del Plata, Argentina
- 1275.10.54009 Boehringer Ingelheim Investigational Site
-
Salta, Argentina
- 1275.10.54004 Boehringer Ingelheim Investigational Site
-
San Isidro, Argentina
- 1275.10.54001 Boehringer Ingelheim Investigational Site
-
Zarate, Argentina
- 1275.10.54010 Boehringer Ingelheim Investigational Site
-
-
-
-
New South Wales
-
Cardiff, New South Wales, Australia
- 1275.10.61008 Boehringer Ingelheim Investigational Site
-
-
Victoria
-
East Ringwood, Victoria, Australia
- 1275.10.61002 Boehringer Ingelheim Investigational Site
-
Heidelberg Heights, Victoria, Australia
- 1275.10.61001 Boehringer Ingelheim Investigational Site
-
-
Western Australia
-
Mirrabooka, Western Australia, Australia
- 1275.10.61009 Boehringer Ingelheim Investigational Site
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada
- 1275.10.02004 Boehringer Ingelheim Investigational Site
-
Red Deer, Alberta, Canada
- 1275.10.02001 Boehringer Ingelheim Investigational Site
-
-
British Columbia
-
Chilliwack, British Columbia, Canada
- 1275.10.02003 Boehringer Ingelheim Investigational Site
-
Coquitlam, British Columbia, Canada
- 1275.10.02009 Boehringer Ingelheim Investigational Site
-
Vancouver, British Columbia, Canada
- 1275.10.02012 Boehringer Ingelheim Investigational Site
-
-
Manitoba
-
Winnipeg, Manitoba, Canada
- 1275.10.02006 Boehringer Ingelheim Investigational Site
-
Winnipeg, Manitoba, Canada
- 1275.10.02008 Boehringer Ingelheim Investigational Site
-
-
New Brunswick
-
Moncton, New Brunswick, Canada
- 1275.10.02005 Boehringer Ingelheim Investigational Site
-
-
Ontario
-
Burlington, Ontario, Canada
- 1275.10.02013 Boehringer Ingelheim Investigational Site
-
Strathroy, Ontario, Canada
- 1275.10.02002 Boehringer Ingelheim Investigational Site
-
Sudbury, Ontario, Canada
- 1275.10.02007 Boehringer Ingelheim Investigational Site
-
-
Quebec
-
Drummondville, Quebec, Canada
- 1275.10.02011 Boehringer Ingelheim Investigational Site
-
Montreal, Quebec, Canada
- 1275.10.02010 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Ávila, El Salvador
- 1275.10.34014 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Asslar, Germany
- 1275.10.49007 Boehringer Ingelheim Investigational Site
-
Berlin, Germany
- 1275.10.49014 Boehringer Ingelheim Investigational Site
-
Elsterwerda, Germany
- 1275.10.49016 Boehringer Ingelheim Investigational Site
-
Hamburg, Germany
- 1275.10.49012 Boehringer Ingelheim Investigational Site
-
Hatten, Germany
- 1275.10.49005 Boehringer Ingelheim Investigational Site
-
Kiel Kronshagen, Germany
- 1275.10.49008 Boehringer Ingelheim Investigational Site
-
Köln, Germany
- 1275.10.49004 Boehringer Ingelheim Investigational Site
-
Lübeck, Germany
- 1275.10.49010 Boehringer Ingelheim Investigational Site
-
Münster, Germany
- 1275.10.49003 Boehringer Ingelheim Investigational Site
-
Pirna, Germany
- 1275.10.49006 Boehringer Ingelheim Investigational Site
-
St. Ingbert/Oberwürzbach, Germany
- 1275.10.49013 Boehringer Ingelheim Investigational Site
-
Unterschneidheim, Germany
- 1275.10.49001 Boehringer Ingelheim Investigational Site
-
Wangen, Germany
- 1275.10.49015 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Ancona, Italy
- 1275.10.39005 Boehringer Ingelheim Investigational Site
-
Catania, Italy
- 1275.10.39006 Boehringer Ingelheim Investigational Site
-
Catania, Italy
- 1275.10.39009 Boehringer Ingelheim Investigational Site
-
Catania, Italy
- 1275.10.39014 Boehringer Ingelheim Investigational Site
-
Latina, Italy
- 1275.10.39007 Boehringer Ingelheim Investigational Site
-
Milano, Italy
- 1275.10.39012 Boehringer Ingelheim Investigational Site
-
Milano, Italy
- 1275.10.39013 Boehringer Ingelheim Investigational Site
-
Olbia (OT), Italy
- 1275.10.39015 Boehringer Ingelheim Investigational Site
-
Orbassano (TO), Italy
- 1275.10.39016 Boehringer Ingelheim Investigational Site
-
Palermo, Italy
- 1275.10.39004 Boehringer Ingelheim Investigational Site
-
Pistoia, Italy
- 1275.10.39003 Boehringer Ingelheim Investigational Site
-
Roma, Italy
- 1275.10.39008 Boehringer Ingelheim Investigational Site
-
Sesto San Giovanni (MI), Italy
- 1275.10.39001 Boehringer Ingelheim Investigational Site
-
Siena, Italy
- 1275.10.39010 Boehringer Ingelheim Investigational Site
-
Terni, Italy
- 1275.10.39011 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Cantanhede, Portugal
- 1275.10.35104 Boehringer Ingelheim Investigational Site
-
Porto, Portugal
- 1275.10.35112 Boehringer Ingelheim Investigational Site
-
Sandim, Portugal
- 1275.10.35103 Boehringer Ingelheim Investigational Site
-
Tornada, Portugal
- 1275.10.35105 Boehringer Ingelheim Investigational Site
-
Valadares, Portugal
- 1275.10.35108 Boehringer Ingelheim Investigational Site
-
Vila Nova de Gaia, Portugal
- 1275.10.35101 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Chelyabinsk, Russian Federation
- 1275.10.07004 Boehringer Ingelheim Investigational Site
-
Saint-Petersburg, Russian Federation
- 1275.10.07006 Boehringer Ingelheim Investigational Site
-
Saratov, Russian Federation
- 1275.10.07001 Boehringer Ingelheim Investigational Site
-
Saratov, Russian Federation
- 1275.10.07005 Boehringer Ingelheim Investigational Site
-
St. Petersburg, Russian Federation
- 1275.10.07003 Boehringer Ingelheim Investigational Site
-
Yaroslavl, Russian Federation
- 1275.10.07002 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Barcelona, Spain
- 1275.10.34003 Boehringer Ingelheim Investigational Site
-
Canet de Mar, Spain
- 1275.10.34004 Boehringer Ingelheim Investigational Site
-
Centelles, Spain
- 1275.10.34008 Boehringer Ingelheim Investigational Site
-
L'Hospitalet de Llobregat (Barcelona), Spain
- 1275.10.34009 Boehringer Ingelheim Investigational Site
-
La Roca del Vallès, Spain
- 1275.10.34012 Boehringer Ingelheim Investigational Site
-
Madrid, Spain
- 1275.10.34006 Boehringer Ingelheim Investigational Site
-
Malaga, Spain
- 1275.10.34010 Boehringer Ingelheim Investigational Site
-
Mataró, Spain
- 1275.10.34011 Boehringer Ingelheim Investigational Site
-
Málaga, Spain
- 1275.10.34001 Boehringer Ingelheim Investigational Site
-
Pineda de Mar, Spain
- 1275.10.34013 Boehringer Ingelheim Investigational Site
-
Sabadell, Spain
- 1275.10.34002 Boehringer Ingelheim Investigational Site
-
Tarragona, Spain
- 1275.10.34005 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Chernivtsi, Ukraine
- 1275.10.38006 Boehringer Ingelheim Investigational Site
-
Dnipropetrovs'k, Ukraine
- 1275.10.38007 Boehringer Ingelheim Investigational Site
-
Kiev, Ukraine
- 1275.10.38002 Boehringer Ingelheim Investigational Site
-
Kiev, Ukraine
- 1275.10.38003 Boehringer Ingelheim Investigational Site
-
Lviv, Ukraine
- 1275.10.38004 Boehringer Ingelheim Investigational Site
-
Vinnitsa, Ukraine
- 1275.10.38001 Boehringer Ingelheim Investigational Site
-
Zhytomyr, Ukraine
- 1275.10.38005 Boehringer Ingelheim Investigational Site
-
-
-
-
California
-
Chino, California, United States
- 1275.10.01019 Boehringer Ingelheim Investigational Site
-
Huntington Beach, California, United States
- 1275.10.01008 Boehringer Ingelheim Investigational Site
-
San Diego, California, United States
- 1275.10.01003 Boehringer Ingelheim Investigational Site
-
San Diego, California, United States
- 1275.10.01024 Boehringer Ingelheim Investigational Site
-
Sylmar, California, United States
- 1275.10.01002 Boehringer Ingelheim Investigational Site
-
-
Florida
-
Miami, Florida, United States
- 1275.10.01011 Boehringer Ingelheim Investigational Site
-
Orlando, Florida, United States
- 1275.10.01009 Boehringer Ingelheim Investigational Site
-
Oviedo, Florida, United States
- 1275.10.01023 Boehringer Ingelheim Investigational Site
-
Tamarac, Florida, United States
- 1275.10.01006 Boehringer Ingelheim Investigational Site
-
-
Georgia
-
Conyers, Georgia, United States
- 1275.10.01017 Boehringer Ingelheim Investigational Site
-
Snellville, Georgia, United States
- 1275.10.01016 Boehringer Ingelheim Investigational Site
-
-
Indiana
-
Avon, Indiana, United States
- 1275.10.01012 Boehringer Ingelheim Investigational Site
-
Muncie, Indiana, United States
- 1275.10.01013 Boehringer Ingelheim Investigational Site
-
-
Maryland
-
Elkton, Maryland, United States
- 1275.10.01010 Boehringer Ingelheim Investigational Site
-
-
Michigan
-
Stevensville, Michigan, United States
- 1275.10.01001 Boehringer Ingelheim Investigational Site
-
-
North Carolina
-
Salisbury, North Carolina, United States
- 1275.10.01007 Boehringer Ingelheim Investigational Site
-
-
North Dakota
-
Bismarck, North Dakota, United States
- 1275.10.01005 Boehringer Ingelheim Investigational Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States
- 1275.10.01020 Boehringer Ingelheim Investigational Site
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States
- 1275.10.01022 Boehringer Ingelheim Investigational Site
-
-
South Carolina
-
Union, South Carolina, United States
- 1275.10.01021 Boehringer Ingelheim Investigational Site
-
-
Texas
-
North Richland Hills, Texas, United States
- 1275.10.01014 Boehringer Ingelheim Investigational Site
-
-
Utah
-
Draper, Utah, United States
- 1275.10.01018 Boehringer Ingelheim Investigational Site
-
-
Virginia
-
Richmond, Virginia, United States
- 1275.10.01015 Boehringer Ingelheim Investigational Site
-
Virginia Beach, Virginia, United States
- 1275.10.01025 Boehringer Ingelheim Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Signed and dated ICF (Informed Consent Form)
- Male or female on diet and exercise regime and on stable background metformin > or equal to 1500 mg or maximun dose according to local label
- HBA1c (Glicoslated Hemoglobin) > or equal to 8% and < or equal to 10.5 % at Visit 1
- HbA1c > or equal to 7 and < or equal to 10.5 at Visit 4
- Age > or equal to 18 years
- BMI (Body Mass Index) < or equal to 45
Exclusion criteria:
- Uncontrolled hyperglycemia during open label period and placebo add on "run-in" period
- Use of any other antidiabetic
- Renal function below 60 ml/min/1.73 m2
- Antiobesity drugs or aggresive diets
- Gastorintestinal surgeries
- Current systemic steroids or uncontrolled endocrine disorders other than Diabetes Type 2
- Acute coronary syndrome and stroke within 3 months of informed consent
- Known allergies to DPP-IV (Dypeptidil Peptidase IV) or SGLT-2 (Sodium Glucose Transporter 2) inhibitors
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Empagliflozin 10 mg dose
Empagliflozin open label treatment period
|
Empagliflozin active
|
Experimental: Placebo add on 10 mg dose
Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo add on run-in
|
Empagliflozin active
Empagliflozin / Linagliptin 10/5 mg Dose placebo FDC
Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo
|
Experimental: Empagliflozin/Linagliptin 25/5 mg Dose
Empagliflozin / Linagliptin 25/5 mg Dose FDC active
|
Empagliflozin placebo
Empagliflozin / Linagliptin 25/5 mg Dose FDC active
Empagliflozin / Linagliptin 10/5 mg Dose FDC active
|
Experimental: Empagliflozin/Linagliptin 10/5 mg Dose.
Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo
|
Empagliflozin active
Empagliflozin / Linagliptin 10/5 mg Dose placebo FDC
Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo
|
Experimental: Empagliflozin/Linagliptin 10/5 mg Dose
Empagliflozin / Linagliptin 10/5 mg Dose FDC active
|
Empagliflozin placebo
Empagliflozin / Linagliptin 25/5 mg Dose FDC active
Empagliflozin / Linagliptin 10/5 mg Dose FDC active
|
Experimental: Empagliflozin 25 mg dose
Empagliflozin open label treatment period
|
Empagliflozin active
|
Experimental: Empagliflozin/Linagliptin 25/5 mg Dose.
Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
|
Empagliflozin active
Empagliflozin / Linagliptin 10/5 mg Dose placebo FDC
Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo
|
Experimental: Placebo add on 25 mg dose
Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo add on run-in
|
Empagliflozin active
Empagliflozin / Linagliptin 10/5 mg Dose placebo FDC
Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline of HbA1c After 24 Weeks of Treatment.
Time Frame: Baseline and 24 weeks
|
Change from baseline in Glycated haemoglobin (HbA1c) [%] after 24 weeks of treatment with double-blind trial medication, i.e. HbA1c change from baseline at Week 24. The term "baseline" was not used to refer to measurements prior to the administration of open-label medication. Such measurements were referred to as "pre-treatment". Analyses of change from pre-treatment used the last value before first administration of open-label medication as point of reference. Observed Case (OC): This method analyse only available data that were observed while patients were on treatment, i.e., excluding the missing data. All values measured after rescue medication taken were set to missing. Full Analysis Set (FAS): Includes all patients in the Treated set who had a baseline HbA1c assessment and at least 1 on-treatment HbA1c assessment during the double-blind part of the trial. |
Baseline and 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fasting Plasma Glucose (FPG) Change From Baseline at 24 Weeks.
Time Frame: Baseline and 24 weeks
|
Change from baseline FPG (mmol/L) after 24 weeks of treatment with double-blind trial medication, i.e.
FPG change from baseline at Week 24.
|
Baseline and 24 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Protease Inhibitors
- Incretins
- Sodium-Glucose Transporter 2 Inhibitors
- Dipeptidyl-Peptidase IV Inhibitors
- Empagliflozin
- Linagliptin
Other Study ID Numbers
- 1275.10
- 2012-002271-34 (EudraCT Number: EudraCT)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
AstraZenecaNot yet recruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on BI 10773
-
Boehringer IngelheimCompletedDiabetes Mellitus, Type 2Germany
-
Boehringer IngelheimEli Lilly and CompanyCompletedDiabetes Mellitus, Type 2United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Croatia, Czech Republic, Denmark, Estonia, France, Georgia, Greece, Hong Kong, Hungary, India, Indonesia, Israel, Italy, Japan, Korea, Republic of, Malaysia and more
-
Boehringer IngelheimEli Lilly and CompanyCompletedDiabetes Mellitus, Type 2United States, Denmark, France, Ireland, Korea, Republic of, Portugal, United Kingdom
-
Boehringer IngelheimEli Lilly and CompanyCompletedDiabetes Mellitus, Type 2United States, Canada, China, France, Germany, India, Korea, Republic of, Mexico, Slovakia, Slovenia, Taiwan, Turkey
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompletedDiabetes Mellitus, Type 2Germany
-
Boehringer IngelheimEli Lilly and CompanyCompletedDiabetes Mellitus, Type 2United States, Argentina, Australia, Brazil, Bulgaria, Canada, Colombia, Denmark, Estonia, Hungary, Italy, Lebanon, Malaysia, Mexico, Peru, Philippines, Poland, Romania, Russian Federation, Spain, Sweden, Taiwan
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted